Trump Order Boosts Interest in Psychedelic Drug Sector
Trump issued an executive order to speed up psychedelic drug development. The move boosted investor interest despite warnings of long clinical timelines.
Xurve View
Insights:
Xurve View
The United States executive order to accelerate psychedelic drug development may help attract more capital into the mental health sector. Nine executives and investors told Reuters the order could shorten administrative timelines by improving coordination between federal regulators. This shift signals a federal backing that could finally draw institutional capital into a historically niche asset class.
